rs74799832
|
|
|
0.900 |
GeneticVariation |
BEFREE |
One patient having a mutation in exon 16 (Met918Thr) presented with the MEN2B phenotype, six patients from two families had hereditary MTC without pheochromocytoma (pheo) and primary hyperparathyroidism (PHPT), whereas 33 patients from 15 families showed the MEN2A phenotype.
|
16865647 |
2006 |
rs74799832
|
|
|
0.900 |
GeneticVariation |
BEFREE |
We identified seven familial and 68 de novo cases of MEN2B; 61 exhibited the RET M918T genotype (2 others exhibited A883F and E768D/L790T mutations).
|
29077903 |
2018 |
rs74799832
|
|
|
0.900 |
GeneticVariation |
UNIPROT |
Guidelines for diagnosis and therapy of MEN type 1 and type 2.
|
11739416 |
2001 |
rs74799832
|
|
|
0.900 |
GeneticVariation |
UNIPROT |
ACMG policy statement: updated recommendations regarding analysis and reporting of secondary findings in clinical genome-scale sequencing.
|
25356965 |
2015 |
rs74799832
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Mutation analysis of exon 16 of the RET proto-oncogene revealed germline M918T and thus, a molecular diagnosis of multiple endocrine neoplasia type 2B (MEN 2B).
|
10369718 |
1999 |
rs74799832
|
|
|
0.900 |
GeneticVariation |
BEFREE |
All MEN 2B patients showed an ATG to ACG (Met918Thr) mutation.
|
11900218 |
2002 |
rs74799832
|
|
|
0.900 |
GeneticVariation |
BEFREE |
A family with MEN-2B due to RET-A883F mutation displayed a less aggressive form of MTC than what is usually seen in patients with RET-M918T mutation.
|
21186952 |
2011 |
rs74799832
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Forty-four MEN 2B patients carrying inherited (3 patients) and de novo (41 patients) M918T RET mutations were examined for signs and symptoms prompting MEN 2B.
|
23979292 |
2014 |
rs74799832
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Single oligoarray-based detection of specific M918T mutation in RET oncogene in multiple endocrine neoplasia type 2B.
|
21253810 |
2011 |
rs74799832
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Germline mutations in codon 918 of exon 16 of the RET gene (M918T) are classically associated with multiple endocrine neoplasia type 2B</span> (MEN 2B) with highly aggressive medullary thyroid cancer (MTC), pheochromocytoma and a unique phenotype.
|
27807060 |
2016 |
rs74799832
|
|
|
0.900 |
GeneticVariation |
UNIPROT |
The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis.
|
8918855 |
1996 |
rs74799832
|
|
|
0.900 |
GeneticVariation |
UNIPROT |
Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics.
|
27854360 |
2017 |
rs74799832
|
|
|
0.900 |
GeneticVariation |
BEFREE |
In multiple endocrine neoplasia 2B (MEN-2B) patients expressing RET(M918T), nuclear enrichment of STAT3 and elevated expression of CXCR4 was detected in metastatic thyroid C-cell carcinoma in the liver.
|
15485908 |
2004 |
rs74799832
|
|
|
0.900 |
GeneticVariation |
BEFREE |
More than 95% of MEN2B patients also had a predominant mutation type at codon 918 (Met-->Thr).
|
11839664 |
2002 |
rs74799832
|
|
|
0.900 |
GeneticVariation |
UNIPROT |
Clinical utility gene card for: multiple endocrine neoplasia type 2.
|
21863057 |
2012 |
rs74799832
|
|
|
0.900 |
GeneticVariation |
UNIPROT |
Medullary thyroid cancer: management guidelines of the American Thyroid Association.
|
19469690 |
2009 |
rs74799832
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Although there were no syndromic features or a positive family history, mutation analysis of the RET proto-oncogene showed a de novo germline Met918Thr mutation in both patients, confirming the diagnosis of multiple endocrine neoplasia type 2B (MEN 2B).
|
16808642 |
2006 |
rs74799832
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Thus, while our results support the conclusion that the Met918Thr substitution is responsible for MEN2B, they suggest that the substrate specificity of the RET kinase does not interfere with its normal role in the development of the kidneys and enteric nervous system.
|
10675330 |
2000 |
rs74799832
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Moreover, one proband was identified with multiple endocrine neoplasia type 2B and carried a de novo mutation of M918T.
|
26254625 |
2016 |
rs74799832
|
|
|
0.900 |
GeneticVariation |
BEFREE |
They are represented by the Met918Thr substitution (exon 16) typical of Multiple Endocrine Neoplasia type 2B (MEN2B) and, to a lesser extent, by nucleotide changes occurring at one of five critical cysteine residues (exons 10 and 11) typical of MEN type 2A (MEN2A).
|
9191060 |
1997 |
rs74799832
|
|
|
0.900 |
GeneticVariation |
BEFREE |
More than 90% of M918T carriers with multiple endocrine neoplasia type 2B (MEN 2B) harbor de novo mutations in the REarranged during Transfection (RET) protooncogene.
|
19041016 |
2008 |
rs74799832
|
|
|
0.900 |
GeneticVariation |
UNIPROT |
ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing.
|
23788249 |
2013 |
rs74799832
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Multiple endocrine neoplasia type 2B is a rare syndrome caused mainly by Met918Thr germline RET mutation, and characterised by medullary thyroid carcinoma, phaeochromocytoma, and extra-endocrine features.
|
30660595 |
2019 |
rs74799832
|
|
|
0.900 |
GeneticVariation |
BEFREE |
We also examined the sensitivity of RET (M918T), a RET mutation prevalent in aggressive multiple endocrine neoplasia type 2B, to these TKIs in the context of BaF3/KR cells.
|
29908090 |
2018 |
rs74799832
|
|
|
0.900 |
GeneticVariation |
UNIPROT |
Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline.
|
24893135 |
2014 |